Researchers combined data from five clinical trials to see if a class of diabetes drugs called GLP-1 receptor agonists could help with the motor symptoms of Parkinson's disease. The analysis included 708 people with Parkinson's who were randomly assigned to receive either the drug or a placebo. The main goal was to see if the drugs improved scores on a standard test of movement, both when patients were taking their regular Parkinson's medication and when they were not.
The combined results showed no statistically significant improvement in motor scores for the group taking the GLP-1 drugs compared to the placebo group. This means the analysis could not confirm a clear benefit for movement symptoms. However, people taking the GLP-1 drugs were more likely to experience stomach-related side effects like nausea, vomiting, constipation, and weight loss.
It's important to understand this was a meta-analysis, which is a way of statistically combining results from separate, completed studies. The individual trials in this analysis were relatively small, and the combined result shows the possibility of no effect or even harm. For people with Parkinson's, this analysis suggests that, based on current evidence, GLP-1 drugs do not show a proven benefit for motor symptoms and come with a known risk of gastrointestinal side effects.
